皮膚科薬市場：疾患別（にきび、皮膚炎、乾癬、皮膚がん、酒さ、脱毛症、その他）、タイプ別（処方薬、市販薬）、投与経路別（局所投与、経口投与、非経口投与）。世界の機会分析および産業予測、2021年--2030年

Dermatologicals Market by Disease (Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, Alopecia, and Others), Type (Prescription-based Drugs, and Over-the-Counter Drugs), and Route of Administration (Topical Administration, Oral Administration, and Parenteral Administration): Global Opportunity Analysis and Industry Forecast, 2021––2030

皮膚科学の世界市場は、2020年には199億7430万ドルで、2021年から2030年までのCAGRは11.5%を記録し、2030年には593億930万ドルに達すると予測されています。皮膚科領域は、皮膚疾患を患う患者の治療に使用さ... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Allied Market Research アライドマーケットリサーチ	2022年1月18日	US$6,168 シングルユーザーライセンスライセンス・価格情報注文方法はこちら	262	英語

サマリー

皮膚科学の世界市場は、2020年には199億7430万ドルで、2021年から2030年までのCAGRは11.5%を記録し、2030年には593億930万ドルに達すると予測されています。

皮膚科領域は、皮膚疾患を患う患者の治療に使用される医薬品の一種である。これらの製剤は、乾癬、にきび、酒さなどの症状の治療に使用されます。市場には、局所用、非経口用、経口用など、さまざまな種類の皮膚科製剤が出回っています。皮膚疾患の治療は、症状の種類や重症度によって処方されます。例えば、乾癬の治療には、非経口的な皮膚科製剤の使用が必要です。

皮膚科領域の世界市場の成長は、ニキビ、アトピー性皮膚炎、乾癬、酒さなどの皮膚疾患の顕著な増加、皮膚疾患に関する知識の普及を目的とした政府の取り組みの増加、皮膚科治療薬の製造数の急増、医療サービスに対する支出の増加、スキンケア製品の採用数の増加が主な原因となっています。例えば、米国皮膚科学会は、皮膚科治療のフロンティアを開拓し、十分なサービスを受けていない人々への皮膚科サービスを増やすことを目的としています。このプログラムはさらに、認定皮膚科医によるケアの重要性について、消費者の理解を深めることを目的としています。また、COVID-19に罹患し、蕁麻疹や扁平紅斑、扁平紅斑などの皮膚疾患を発症した患者さんには、皮膚科の薬剤が処方されます。

また、10代や20代の若年層が増加していることも、市場の成長を後押ししています。これは、10代はホルモンレベルの変化により、ニキビなどの皮膚疾患にかかりやすいため、より良い健康状態を保つために様々な皮膚科治療薬の需要が高まっているためと考えられています。このような要因が、世界の皮膚科治療薬市場の成長に大きく貢献すると期待されています。
また、製薬業界の発展も皮膚科分野の世界市場を牽引する大きな要因となっています。さらに、臨床試験数の増加も市場の成長に大きく寄与しています。臨床研究は、皮膚科製品の安全性と有効性を評価することを目的としています。皮膚科製品の承認数の増加は、世界市場の主要な推進力として機能します。例えば、2021年12月、バイオ医薬品会社であるAmgenは、プラーク乾癬と診断された患者の治療に推奨されるOtezla（apremilast）のFDA（食品医薬品局）承認を発表しました。
さらに、各国政府や民間団体による医薬品製造装置の開発資金の増加が、市場の成長を押し上げると予想されます。例えば、2020年3月、インドの製薬省は、国内の原薬ユニットの強化や医薬品の製造を後押しするために、約13億ドルの投資スキームを発表しました。さらに、製薬業界における研究開発活動の増加は、市場拡大のための有利な機会を提供すると予想されます。

しかし、ニキビやその他の皮膚疾患に対する代替治療法があることが、市場の成長を阻害しています。一方、皮膚疾患に対するさまざまな治療法に関する人々の意識の高まりは、皮膚科市場の成長を増大させます。このことは、多くの主要企業の新興市場参入をさらに促し、皮膚科市場拡大のための有利な機会を提供しています。
皮膚科学の世界市場は、疾患、タイプ、投与経路、地域に区分されます。疾患別では、にきび、皮膚炎、乾癬、皮膚がん、酒さ、脱毛症、その他に分類されます。タイプ別では、処方薬と一般用医薬品に細分化されます。投与経路では、局所投与、経口投与、非経口投与に分類されます。地域別では、北米、欧州、アジア太平洋地域、LAMEAで分析されています。

皮膚科学の世界市場で事業を展開している主要企業には、AbbVie Inc.(Allergan PLC）、Amgen Inc.、Galderma、GlaxoSmithKline Plc.、Johnson & Johnson Services Inc、Leo Pharma A/S、Novartis AG、Organon & Co（Merck）、Pfizer Inc、Sun Pharmaceutical Industries Limitedなどです。

ステークホルダーにとっての主なメリット

本レポートは、皮膚科学の世界市場規模を現在の動向と将来予測とともに詳細に分析し、差し迫った投資ポケットを解明するものです。
2021年から2030年までの市場分析を提供しており、利害関係者が市場に存在する機会を活用することを可能にすると期待されます。
地域に関する包括的な分析は、地域市場を理解し、戦略的な事業計画を促進し、優勢な機会を決定するのに役立ちます。
主要企業のプロファイルと成長戦略を徹底的に分析し、世界の皮膚科市場の競争展望を理解します。

主要な市場セグメント
#疾患別
#にきび
#皮膚炎
#乾癬
#皮膚がん
#酒さ
##脱毛症
##その他

#タイプ別
##処方箋に基づく医薬品
#一般用医薬品

#投与経路別
##外用剤
##♪経口投与
##非経口投与

#地域別
##北アメリカ
###米国
###カナダ
###メキシコ
##ヨーロッパ
###ドイツ
###フランス
###イギリス
###イタリア
###スペイン
###その他のヨーロッパ
##アジア太平洋
###日本
###中国
###オーストラリア
###インド
###韓国
###その他のアジア太平洋地域
#ラメア
###ブラジル
###サウジアラビア
###南アフリカ
###LAMEAの残りの地域

主要な市場関係者
#AbbVie Inc.(Allergan PLC)です。
#アムジェン社
#ガルデルマ
#グラクソ・スミスクライン・ピーエルシー
#ジョンソン・エンド・ジョンソンサービス株式会社
#レオファーマA/S
#ノバルティスAG
#Organon & Co (Merck)
#ファイザー株式会社
#サンファーマシューティカルインダストリー株式会社

ページTOPに戻る

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in prevalence of skin diseases
3.5.1.2.Increase in number of approval for dermatological products
3.5.1.3.Rise in awareness among individuals regarding skin diseases

3.5.2.Restraint

3.5.2.1.Availability of alternatives for acne treatment

3.5.3.Opportunities

3.5.3.1.Increase in healthcare expenditure
3.5.3.2.Development of pharmaceutical industry

3.5.4.Impact analysis

3.6.Impact analysis of COVID-19 on the dermatologicals market

CHAPTER 4:DERMATOLOGICALS MARKET, BY DISEASE

4.1.Overview

4.1.1.Market size and forecast

4.2.Acne

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Dermatitis

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Psoriasis

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Skin cancer

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.Rosacea

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

4.7.Alopecia

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country

4.8.Others

4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country

CHAPTER 5:DERMATOLOGICALS MARKET, BY TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Prescription-based drugs

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country

5.3.Over-the-counter drugs

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country

CHAPTER 6:DERMATOLOGICALS MARKET, BY ROUTE OF ADMINISTRATION

6.1.Overview

6.1.1.Market size and forecast

6.2.Topical administration

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country

6.3.Oral administration

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country

6.4.Parenteral administration

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country

CHAPTER 7:DERMATOLOGICALS MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America dermatologicals market, by disease
7.2.3.North America dermatologicals market, by type
7.2.4.North America dermatologicals market, by route of administration
7.2.5.Market size and forecast, by country

7.2.5.1.U.S.

7.2.5.1.1.U.S. dermatologicals market, by disease
7.2.5.1.2.U.S. dermatologicals market, by type
7.2.5.1.3.U.S. dermatologicals market, by route of administration

7.2.5.2.Canada

7.2.5.2.1.Canada dermatologicals market, by disease
7.2.5.2.2.Canada dermatologicals market, by type
7.2.5.2.3.Canada dermatologicals market, by route of administration

7.2.5.3.Mexico

7.2.5.3.1.Mexico dermatologicals market, by disease
7.2.5.3.2.Mexico dermatologicals market, by type
7.2.5.3.3.Mexico dermatologicals market, by route of administration

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe dermatologicals market, by disease
7.3.3.Europe dermatologicals market, by type
7.3.4.Europe dermatologicals market, by route of administration
7.3.5.Market size and forecast, by country

7.3.5.1.Germany

7.3.5.1.1.Germany dermatologicals market, by disease
7.3.5.1.2.Germany dermatologicals market, by type
7.3.5.1.3.Germany dermatologicals market, by route of administration

7.3.5.2.France

7.3.5.2.1.France dermatologicals market, by disease
7.3.5.2.2.France dermatologicals market, by type
7.3.5.2.3.France dermatologicals market, by route of administration

7.3.5.3.UK

7.3.5.3.1.UK dermatologicals market, by disease
7.3.5.3.2.UK dermatologicals market, by type
7.3.5.3.3.UK dermatologicals market, by route of administration

7.3.5.4.Italy

7.3.5.4.1.Italy dermatologicals market, by disease
7.3.5.4.2.Italy dermatologicals market, by type
7.3.5.4.3.Italy dermatologicals market, by route of administration

7.3.5.5.Spain

7.3.5.5.1.Spain dermatologicals market, by disease
7.3.5.5.2.Spain dermatologicals market, by type
7.3.5.5.3.Spain dermatologicals market, by route of administration

7.3.5.6.Rest of Europe

7.3.5.6.1.Rest of Europe dermatologicals market, by disease
7.3.5.6.2.Rest of Europe dermatologicals market, by type
7.3.5.6.3.Rest of Europe dermatologicals market, by route of administration

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific dermatologicals market, by disease
7.4.3.Asia-Pacific dermatologicals market, by type
7.4.4.Asia-Pacific dermatologicals market, by route of administration
7.4.5.Market size and forecast, by country

7.4.5.1.Japan

7.4.5.1.1.Japan dermatologicals market, by disease
7.4.5.1.2.Japan dermatologicals market, by type
7.4.5.1.3.Japan dermatologicals market, by route of administration

7.4.5.2.China

7.4.5.2.1.China dermatologicals market, by disease
7.4.5.2.2.China dermatologicals market, by type
7.4.5.2.3.China dermatologicals market, by route of administration

7.4.5.3.Australia

7.4.5.3.1.Australia dermatologicals market, by disease
7.4.5.3.2.Australia dermatologicals market, by type
7.4.5.3.3.Australia dermatologicals market, by route of administration

7.4.5.4.India

7.4.5.4.1.India dermatologicals market, by disease
7.4.5.4.2.India dermatologicals market, by type
7.4.5.4.3.India dermatologicals market, by route of administration

7.4.5.5.South Korea

7.4.5.5.1.South Korea dermatologicals market, by disease
7.4.5.5.2.South Korea dermatologicals market, by type
7.4.5.5.3.South Korea dermatologicals market, by route of administration

7.4.5.6.Rest of Asia-Pacific

7.4.5.6.1.Rest of Asia-Pacific dermatologicals market, by disease
7.4.5.6.2.Rest of Asia-Pacific dermatologicals market, by type
7.4.5.6.3.Rest of Asia-Pacific dermatologicals market, by route of administration

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA dermatologicals market, by disease
7.5.3.LAMEA dermatologicals market, by type
7.5.4.LAMEA dermatologicals market, by route of administration
7.5.5.Market size and forecast, by country

7.5.5.1.Brazil

7.5.5.1.1.Brazil dermatologicals market, by disease
7.5.5.1.2.Brazil dermatologicals market, by type
7.5.5.1.3.Brazil dermatologicals market, by route of administration

7.5.5.2.Saudi Arabia

7.5.5.2.1.Saudi Arabia dermatologicals market, by disease
7.5.5.2.2.Saudi Arabia dermatologicals market, by type
7.5.5.2.3.Saudi Arabia dermatologicals market, by route of administration

7.5.5.3.South Africa

7.5.5.3.1.South Africa dermatologicals market, by disease
7.5.5.3.2.South Africa dermatologicals market, by type
7.5.5.3.3.South Africa dermatologicals market, by route of administration

7.5.5.4.Rest of LAMEA

7.5.5.4.1.Rest of LAMEA dermatologicals market, by disease
7.5.5.4.2.Rest of LAMEA dermatologicals market, by type
7.5.5.4.3.Rest of LAMEA dermatologicals market, by route of administration

CHAPTER 8:COMPANY PROFILES

8.1.ABBVIE INC. (ALLERGAN PLC)

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.AMGEN INC.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.GALDERMA

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Key strategic moves and developments

8.4.GLAXOSMITHKLINE PLC. (GSK)

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.JOHNSON & JOHNSON SERVICES, INC.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.LEO PHARMA A/S

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.NOVARTIS AG

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.ORGANON & CO. (MERCK)

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.PFIZER INC.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product Portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.SUN PHARMACEUTICAL INDUSTRIES LIMITED

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

List of Tables

LIST OF TABLES

TABLE 01.DERMATOLOGICALS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 02.DERMATOLOGICALS MARKET FOR ACNE, BY REGION, 2020–2030 ($MILLION)
TABLE 03.DERMATOLOGICALS MARKET FOR DERMATITIS, BY REGION, 2020–2030 ($MILLION)
TABLE 04.DERMATOLOGICALSMARKET FOR PSORIASIS , BY REGION, 2020–2030 ($MILLION)
TABLE 05.DERMATOLOGICALSMARKET FOR SKIN CANCER, BY REGION, 2020–2030 ($MILLION)
TABLE 06.DERMATOLOGICALSMARKET FOR ROSACEA, BY REGION, 2020–2030 ($MILLION)
TABLE 07.DERMATOLOGICALSMARKET FOR ALOPECIA, BY REGION, 2020–2030 ($MILLION)
TABLE 08.DERMATOLOGICALSMARKET FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 09.DERMATOLOGICALS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 10.DERMATOLOGICALSMARKET FOR PRESCRIPTION-BASED DRUGS, BY REGION, 2020–2030 ($MILLION)
TABLE 11.DERMATOLOGICALSMARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2020–2030 ($MILLION)
TABLE 12.DERMATOLOGICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 13.DERMATOLOGICALSMARKET FOR TOPICAL ADMINISTRATION, BY REGION, 2020–2030 ($MILLION)
TABLE 14.DERMATOLOGICALS MARKET FOR ORAL ADMINISTRATION , BY REGION, 2020–2030 ($MILLION)
TABLE 15.DERMATOLOGICALS MARKET FOR PARENTERAL ADMINISTRATION, BY REGION, 2020–2030 ($MILLION)
TABLE 16.DERMATOLOGICALS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 17.NORTH AMERICA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 18.NORTH AMERICA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 19.NORTH AMERICA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 20.NORTH AMERICA DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 21.U.S. DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 22.U.S. DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 23.U.S. DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 24.CANADA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 25.CANADA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 26.CANADA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 27.MEXICO DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 28.MEXICO DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 29.MEXICO DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 30.EUROPE DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 31.EUROPE DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 32.EUROPE DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 33.EUROPE DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 34.GERMANY DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 35.GERMANY DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 36.GERMANY DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 37.FRANCE DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 38.FRANCE DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 39.FRANCE DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 40.UK DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 41.UK DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 42.UK DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 43.ITALY DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 44.ITALY DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 45.ITALY DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 46.SPAIN DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 47.SPAIN DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 48.SPAIN DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 49.REST OF EUROPE DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 50.REST OF EUROPE DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 51.REST OF EUROPE DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 52.ASIA-PACIFIC DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 53.ASIA-PACIFIC DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 54.ASIA-PACIFIC DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 55.ASIA-PACIFIC DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 56.JAPAN DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 57.JAPAN DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 58.JAPAN DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 59.CHINA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 60.CHINA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 61.CHINA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 62.AUSTRALIA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 63.AUSTRALIA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 64.AUSTRALIA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 65.INDIA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 66.INDIA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 67.INDIA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 68.SOUTH KOREA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 69.SOUTH KOREA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 70.SOUTH KOREA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 74.LAMEA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 75.LAMEA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 76.LAMEA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 77.LAMEA DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 78.BRAZIL DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 79.BRAZIL DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 80.BRAZIL DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 81.SAUDI ARABIA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 82.SAUDI ARABIA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 83.SAUDI ARABIA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 84.SOUTH AFRICA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 85.SOUTH AFRICA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 86.SOUTH AFRICA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 87.REST OF LAMEA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 88.REST OF LAMEA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 89.REST OF LAMEA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 90.ABBVIE: COMPANY SNAPSHOT
TABLE 91.ABBVIE:OPERATING SEGMENT
TABLE 92.ABBVIE: PRODUCT PORTFOLIO
TABLE 93.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94.AMGEN: COMPANY SNAPSHOT
TABLE 95.AMGEN:OPERATING SEGMENT
TABLE 96.AMGEN: PRODUCT PORTFOLIO
TABLE 97.AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98.GLADERMA: COMPANY SNAPSHOT
TABLE 99.GLADERMA:OPERATING SEGMENT
TABLE 100.GLADERMA: PRODUCT PORTFOLIO
TABLE 101.GLADERMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102.GSK: COMPANY SNAPSHOT
TABLE 103.GSK: OPERATING SEGMENTS
TABLE 104.GSK: PRODUCT PORTFOLIO
TABLE 105.GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106.J&J: COMPANY SNAPSHOT
TABLE 107.J&J: OPERATING BUSINESS SEGMENTS
TABLE 108.J&J: PRODUCT PORTFOLIO
TABLE 109.J&J: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 110.LEO PHARMA: COMPANY SNAPSHOT
TABLE 111.LEO PHARMA:OPERATING SEGMENT
TABLE 112.LEO PHARMA: PRODUCT PORTFOLIO
TABLE 113.LEO PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.NOVARTIS: COMPANY SNAPSHOT
TABLE 115.NOVARTIS: OPERATING SEGMENT
TABLE 116.NOVARTIS: PRODUCT PORTFOLIO
TABLE 117.NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118.ORGANON: COMPANY SNAPSHOT
TABLE 119.ORGANON: OPERATING SEGMENTS
TABLE 120.ORGANON: PRODUCT PORTFOLIO
TABLE 121.PFIZER: COMPANY SNAPSHOT
TABLE 122.PFIZER: OPERATING SEGMENTS
TABLE 123.PFIZER: PRODUCT PORTFOLIO
TABLE 124.PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 125.SUN PHARMA: COMPANY SNAPSHOT
TABLE 126.SUN PHARMA: OPERATING SEGMENT
TABLE 127.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 128.SUN PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS

List of Figures

LIST OF FIGURES

FIGURE 01.GLOBAL DERMATOLOGICALS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ACNE, BY COUNTRY, 2020–2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR DERMATITIS, BY COUNTRY, 2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR PSORIASIS, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR SKIN CANCER, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ROSACEA, BY COUNTRY, 2020–2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ALOPECIA, BY COUNTRY, 2020–2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR OTHERS, BY COUNTRY, 2020–2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR PRESCRIPTION-BASED DRUGS, BY COUNTRY, 2020–2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2020–2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR TOPICAL ADMINISTRATION, BY COUNTRY, 2020–2030 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2020–2030 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR PARENTERAL ADMINISTRATION, BY COUNTRY, 2020–2030 (%)
FIGURE 25.ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.ABBVIE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 27.ABBVIE: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 28.AMGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.AMGEN: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 30.AMGEN: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 31.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.GSK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 33.GSK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 34.J&J: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.J&J: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 36.J&J: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 37.LEO PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.LEO PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 39.LEO PHARMA: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 42.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 43.ORGANON: REVENUE, 2018–2020 ($MILLION)
FIGURE 44.ORGANON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 45.ORGANON: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 46.PFIZER: REVENUE, 2018–2020 ($MILLION)
FIGURE 47.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 48.PFIZER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 49.SUN PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 50.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 51.SUN PHARMA: REVENUE SHARE, BY REGION, 2020 (%)

ページTOPに戻る

Table of Contents

Summary

The global dermatologicals market was valued at $19,974.3 million in 2020, and is projected to reach $59,309.3 million by 2030, registering a CAGR of 11.5% from 2021 to 2030.

Dermatologicals are a class of medicine used to treat patients suffering from skin disorders. These preparations are used to treat conditions such as psoriasis, acne, and rosacea. Different types of dermatological formulations are available in the market, including topical, parenteral, and oral. The treatment for skin diseases are prescribed depending upon the type and severity of symptoms. For instance, psoriasis requires the use of parenteral dermatological preparations for treatment.

The growth of the global dermatologicals market is majorly driven by alarming increase in prevalence of skin diseases such as acne, atopic dermatitis, psoriasis, and rosacea; rise in government initiatives to spread awareness & promote knowledge about skin disease; surge in number of dermatological drugs manufacturing; surge in expenditure on human healthcare services; and increase in adoption of skin care products. For instance, the American Academy of Dermatology Association aims to develop frontiers of dermatologic care and increase dermatologic services for under-served population. This program further aims to increase consumer understanding about the importance of care delivered by board-certified dermatologists. Moreover, dermatological products are prescribed to patients suffering from COVID-19 and who develop skin diseases such as urticaria, morbilliform rash, and pernio-like acral lesions.

Furthermore, rise in number of teenagers and younger population drive the growth of the market. This is attributed to the fact that the teenager population is highly vulnerable to skin diseases such as acne, due to change in hormonal level, which boosts the demand for various dermatological drug therapies for better health outcomes. This factors is expected to notably contribute toward the growth of the global dermatologicals market.
In addition, the development of the pharmaceutical sector is a major factor that drives the global dermatologicals market. Moreover, increase in number of clinical studies significantly contributes toward the market growth. Clinical studies aim to evaluate safety and efficacy of dermatological products. Rise in number of approval of dermatological products acts as a key driving force of the global market. For instance, in December 2021, Amgen, a biopharmaceutical company, announced the Food and Drug Administration (FDA) approval of Otezla (apremilast), which is recommended for the treatment of patients diagnosed with plaque psoriasis.
Furthermore, rise in funds by governments of various countries and private organizations to develop pharmaceutical manufacturing units are expected to boost the market growth. For instance, in March 2020, the Department of Pharmaceutical, in India, announced the investment scheme of around $1,300 million to strengthen the domestic active pharmaceutical ingredient units and boost the manufacturing of pharmaceutical products. In addition, increase in R&D activities in pharmaceutical industry is anticipated to provide lucrative opportunities for the market expansion.

However, availability of alternative treatment options for acne and other skin diseases hinders the market growth. On the contrary, increase in awareness among population about various treatments available for skin diseases augments the growth of the dermatologicals market. This has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the expansion of the dermatologicals market.
The global dermatologicals market is segmented into disease, type, route of administration, and region. By disease, the market is categorized into acne, dermatitis, psoriasis, skin cancer, rosacea, alopecia, and others. Depending on type, it is fragmented into prescription-based drugs and over-the-counter drugs. On the basis route of administration, it is segregated topical administration, oral administration, and parenteral administration. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global dermatologicals market are AbbVie Inc. (Allergan PLC)., Amgen Inc., Galderma, GlaxoSmithKline Plc., Johnson & Johnson Services Inc, Leo Pharma A/S, Novartis AG, Organon & Co (Merck), Pfizer Inc., and Sun Pharmaceutical Industries Limited.

KEY BENEFITS FOR STAKEHOLDERS

 The report provides an in-depth analysis of the global dermatologicals market size along with the current trends and future estimations to elucidate the imminent investment pockets.
 It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
 A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
 The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global dermatologicals market.

KEY MARKET SEGMENTS
#By Disease
##Acne
##Dermatitis
##Psoriasis
##Skin Cancer
##Rosacea
##Alopecia
##Others

#By Type
##Prescription-based drugs
##Over-the-Counter drugs

#By Route of Administration
##Topical administration
##Oral administration
##Parenteral administration

#By Region
##North America
###U.S.
###Canada
###Mexico
##Europe
###Germany
###France
###UK
###Italy
###Spain
###Rest of Europe
##Asia-Pacific
###Japan
###China
###Australia
###India
###South Korea
###Rest of Asia-Pacific
##LAMEA
###Brazil
###Saudi Arabia
###South Africa
###Rest of LAMEA

KEY MARKET PLAYERS
#AbbVie Inc. (Allergan PLC).
#Amgen Inc.
#Galderma
#GlaxoSmithKline Plc.
#Johnson & Johnson Services Inc
#Leo Pharma A/S
#Novartis AG
#Organon & Co (Merck)
#Pfizer Inc.
#Sun Pharmaceutical Industries Limited.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（ネットワーク）の最新刊レポート

Allied Market Research社のその他分野での最新刊レポート

本レポートと同じKEY WORD（acne）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

皮膚科薬市場：疾患別（にきび、皮膚炎、乾癬、皮膚がん、酒さ、脱毛症、その他）、タイプ別（処方薬、市販薬）、投与経路別（局所投与、経口投与、非経口投与）。世界の機会分析および産業予測、2021年--2030年

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（ネットワーク）の最新刊レポート

Allied Market Research社のその他分野での最新刊レポート

本レポートと同じKEY WORD（acne）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?